Zydus Cadila launches affordable prostate cancer treatment drug 'Obnyx'

Zydus Cadila announced that it is launching Enzalutamide, a highly effective drug for the treatment of Prostate Cancer, under the brand name 'Obnyx' in India. In a step that can significantly reduce treatment cost by almost 70%, the drug is priced at Rs 5995 (weekly therapy) reducing the monthly treatment cost to less than Rs. 27000. The current MRP of Enzalutamide drug ranges from Rs. 70000 to Rs 80000 for a monthly therapy and can be a huge financial burden for the elderly patients as they need to continue the therapy for a long period of time. This price reduction will benefit many prostate cancer patients to adhere to the treatment.

Powered by Capital Market - Live News